More debate about whether the lowest-risk prostate cancers should even be called "cancer." (Harvard Health Publishing) Four ...
The savings from the new list prices for those drugs were expected to generate about $6 billion for taxpayers and $1.5 billion for Medicare enrollees.
Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...
The drugs treat prostate, breast and blood cancers. About 80,000 people with Medicare Part D coverage used them in a one-year ...
On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.
The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback